Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SCNIBullishCorporate Developmentsnews

High materiality8/10

Scinai expands CDMO backlog to $7.6M, boosting 2026–27 revenue visibility

Oct 13, 2026, 7:40 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Backlog expansion to $7.6M and a $5.1M base fee create tangible near-term revenue visibility; potential $5.85M uncommitted value adds optional upside, though no current commercial volumes exist.

AI summary

What happened, with direct paths to the underlying reporting

Scinai Immunotherapeutics announced a definitive development and clinical manufacturing agreement with a U.S.-based Nasdaq-listed partner, expanding its CDMO backlog. Committed Customer Orders rose to about $7.6 million, up 300% from year-end 2025, supported by a $5.1 million base service commitment and a potential additional $5.85 million later. This provides near-term revenue visibility and improved cash flow through 2027, with optional activities contingent on capacity, pricing, and regulatory progress.

Scinai expands CDMO engagement with $5.1M base service fees.
Committed orders reach $7.6M, up ~300% vs 2025.
Revenue visibility through 2027; potential additional $5.85M later.
No current commercial supply volumes committed; capacity-driven outlook.
Jerusalem and Yavne facilities; ongoing NanoAb collaborations with Max Planck/UM Göttingen.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.